Literature DB >> 17999869

Primary aldosteronism.

Richard J Auchus1, Fiemu E Nwariaku.   

Abstract

Primary aldosteronism is one of the few potentially curable forms of hypertension. This article highlights recent advances in the pathophysiology, diagnosis, and treatment of this relatively common secondary form of hypertension. These topics include the recognition that this disorder is more prevalent than previously assumed, the identification of high-risk populations that benefit most from screening, and the improved approaches to screening, diagnosis, localization, and treatment. This review uses illustrative examples to describe our approach to these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17999869     DOI: 10.1007/BF02938388

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  35 in total

1.  CT characterization of adrenal masses: the time has come.

Authors:  M Korobkin
Journal:  Radiology       Date:  2000-12       Impact factor: 11.105

2.  Hyperaldosteronism among black and white subjects with resistant hypertension.

Authors:  David A Calhoun; Mari K Nishizaka; Mohammad A Zaman; Roopal B Thakkar; Paula Weissmann
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

3.  Distinguishing the antihypertensive and electrolyte effects of eplerenone.

Authors:  D G Levy; R Rocha; J W Funder
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

4.  Changes in left ventricular anatomy and function in hypertension and primary aldosteronism.

Authors:  G P Rossi; A Sacchetto; P Visentin; C Canali; G R Graniero; P Palatini; A C Pessina
Journal:  Hypertension       Date:  1996-05       Impact factor: 10.190

5.  Role for adrenal venous sampling in primary aldosteronism.

Authors:  William F Young; Anthony W Stanson; Geoffrey B Thompson; Clive S Grant; David R Farley; Jon A van Heerden
Journal:  Surgery       Date:  2004-12       Impact factor: 3.982

6.  Endothelial dysfunction in hypertension is independent from the etiology and from vascular structure.

Authors:  D Rizzoni; E Porteri; M Castellano; G Bettoni; M L Muiesan; G Tiberio; S M Giulini; G Rossi; G Bernini; E Agabiti-Rosei
Journal:  Hypertension       Date:  1998-01       Impact factor: 10.190

7.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

8.  Medical management of aldosterone-producing adenomas.

Authors:  R P Ghose; P M Hall; E L Bravo
Journal:  Ann Intern Med       Date:  1999-07-20       Impact factor: 25.391

9.  Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

Authors:  Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

10.  Role of aldosterone in left ventricular hypertrophy in hypertension.

Authors:  Kiyoshi Matsumura; Koji Fujii; Hideyuki Oniki; Masayo Oka; Mitsuo Iida
Journal:  Am J Hypertens       Date:  2006-01       Impact factor: 2.689

View more
  1 in total

1.  Clinical, biochemical, and molecular characterization of macronodular adrenocortical hyperplasia of the zona reticularis: a new syndrome.

Authors:  Hans K Ghayee; Juilee Rege; Lori M Watumull; Fiemu E Nwariaku; Kelley S Carrick; William E Rainey; Walter L Miller; Richard J Auchus
Journal:  J Clin Endocrinol Metab       Date:  2010-11-17       Impact factor: 5.958

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.